A novel multi-parametric high content screening assay in ciPTEC-OAT1 to predict drug-induced nephrotoxicity during drug discovery
- 24 August 2018
- journal article
- research article
- Published by Springer Nature in Archives of Toxicology
- Vol. 92 (10) , 3175-3190
Abstract
Drug-induced nephrotoxicity is a major concern in the clinic and hampers the use of available treatments as well as the development of innovative medicines. It is typically discovered late during drug development, which reflects a lack of in vitro nephrotoxicity assays available that can be employed readily in early drug discovery, to identify and hence steer away from the risk. Here, we report the development of a high content screening assay in ciPTEC-OAT1, a proximal tubular cell line that expresses several relevant renal transporters, using five fluorescent dyes to quantify cell health parameters. We used a validation set of 62 drugs, tested across a relevant concentration range compared to their exposure in humans, to develop a model that integrates multi-parametric data and drug exposure information, which identified most proximal tubular toxic drugs tested (sensitivity 75%) without any false positives (specificity 100%). Due to the relatively high throughput (straight-forward assay protocol, 96-well format, cost-effective) the assay is compatible with the needs in the early drug discovery setting to enable identification, quantification and subsequent mitigation of the risk for nephrotoxicity.Keywords
This publication has 80 references indexed in Scilit:
- Primary porcine proximal tubular cells as an alternative to human primary renal cells in vitro: an initial characterizationBMC Cell Biology, 2013
- Therapeutic and toxic blood concentrations of nearly 1,000 drugs and other xenobioticsCritical Care, 2012
- Tenofovir renal proximal tubular toxicity is regulated By OAT1 and MRP4 transportersLaboratory Investigation, 2011
- Novel conditionally immortalized human proximal tubule cell line expressing functional influx and efflux transportersCell and tissue research, 2009
- IndinavirDrugs, 1999
- LisinoprilDrugs, 1997
- GemfibrozilDrugs, 1996
- AcarboseDrugs, 1993
- MefloquineDrugs, 1993
- ZomepiracDrugs, 1982